Objective: To determine the immune responses of preterm infants(< 37 wks) to hepatitis B vaccine (HBV).
Methods: Study criteria included gestation of 25-37 wks and maternal hepatitis B surface antigen (HBsAg)-positive or unknown. 42 such infants received HBIG and vaccine (5 mcg Recombivax) during the first week of life; the 2nd (HBV-2) and 3rd (HBV-3) doses were given in accordance with AAP guidelines. Sera taken at 1-2 months after the HBV-3 were tested for antihepatitis B antibody by the ELISA technique. A titer of < 10 IU/ml was considered non-immune; between 10 and 100 IU/ml and >100 IU/ml were considered moderate and excellent responses, respectively.
Results: 5/42 infants were non-immune. These infants were born at ≤ 26 (n=2), 27, 32 and 36 weeks gestation. Of those who responded and were between 28 and 34 weeks gestation, 23 infants received the third dose after 7 months of age. Of these, 15 had excellent responses; of the 5 who received HBV-3 at less than 7 months, 1 had excellent response (p <.01).
Conclusion: 88% of preterm infants vaccinated according to current AAP recommendations responded after 3 doses of HBV. Infants ≤ 27 weeks gestation responded poorly. Delaying the 3rd dose of HBV until 7 months or later results in enhanced antibody responses.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
AbuLaimoun, B., Gelardi, N., Cashore, W. et al. IMMUNE RESPONSE OF PRETERM INFANTS TO HEPATITIS B ˙VACCINE.† 595. Pediatr Res 39 (Suppl 4), 102 (1996). https://doi.org/10.1203/00006450-199604001-00616
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-00616